RT Journal Article
SR Electronic
T1 Platelet polyphosphate and SARS-Cov-2 mRNA-vaccine-induced inflammatory side effects: a pilot study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.13.21263437
DO 10.1101/2021.09.13.21263437
A1 Uematsu, Takashi
A1 Sato, Atsushi
A1 Aizawa, Hachidai
A1 Tsujino, Tetsuhiro
A1 Watanabe, Taisuke
A1 Isobe, Kazushige
A1 Kawabata, Hideo
A1 Kitamura, Yutaka
A1 Tanaka, Takaaki
A1 Kawase, Tomoyuki
YR 2021
UL http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263437.abstract
AB Background Platelets have recently been recognized as immune cells. Platelets first contact invading pathogens and then induce immune reactions in cooperation with white blood cells. Platelet polyphosphate (polyP), which is classically recognized as a thrombotic and hemostatic biomolecule, has recently attracted attention as a ‘cytokine’ that modulates inflammation and is involved in intercellular communication between platelets and major immune cells.Objective To determine the involvement of polyP in SARS-Cov-2-mRNA vaccine-induced immune responses, this pilot study examined the effects of mRNA vaccines on platelet polyP levels.Methods Before and after vaccination (BNT162b2), blood samples were obtained from healthy, non-smoking individuals (relatively older male group, n=6 vs. younger female group, n=23), who did not have systemic diseases that required continuous treatment. Washed platelets were prepared and subjected to a fluorometric determination of platelet polyP levels using 4’,6-diamidino-2-phenylindole. The side effects of vaccination were recorded as scores.Results Compared with the male group, platelet polyP levels decreased in the relatively younger female group after the initial dose, while the side effect score increased in the female group after the second dose. Moderate correlation coefficients were observed between the reduction in polyP levels and the side effect scores or the original polyP levels.Conclusions Despite being a pilot study using a small sample size, this study suggests the possibility that platelet polyP may suppress the side effects induced by the mRNA vaccines after the initial dose, but not the second dose, in relatively young female subjects who generally have high immune responsiveness.EssentialsThe COVID-19 mRNA vaccines (BNT162b2) reduced platelet polyP levels after the initial dose, but not after the 2nd dose, in relatively younger female subjects.Relatively older male subjects did not respond to the vaccination by reducing platelet polyP.These findings suggest that platelets release polyP to suppress vaccine-induced reactions, for example, inflammation, which is usually recognized as a side effect.However, such suppression could be observed in subjects with higher immune responses, generally in relatively younger female subjects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by JSPS KAKENHI (grant number 21K09932).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study design and consent forms for all procedures (project identification code: 2019-0423) were approved by the Ethics Committee for Human Participants at the Niigata University School of Medicine (Niigata, Japan) and complied with the Helsinki Declaration of 1964, as revised in 2013.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.